EUVIMEDEUVIMED entdecken
Crossref

Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD‐L1 and PD‐L2

Ryosuke Sato, Hiroki Komatsuda, Takahiro Inoue, Risa Wakisaka, Michihisa Kono iD, Hidekiyo Yamaki, Kenzo Ohara, Takumi Kumai iD, Kan Kishibe, Tatsuya Hayashi, Miki Takahara

Head & Neck · 2024

DOI: 10.1002/hed.27787 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, 2024. Verfasst von Ryosuke Sato und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head & Neck Surgery, Asahikawa Medical University, Asahikawa, Japan. Hauptthemen laut MEDLINE: Nivolumab, B7-H1 Antigen, Head and Neck Neoplasms, Programmed Cell Death 1 Ligand 2 Protein. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Predictive biomarkers for nivolumab in recurrent or metastatic head and neck squamous cell carcinoma (RMHNSCC) have not yet been established.

Methods

The tumor proportion score (TPS), combined positive score (CPS), and soluble forms of programmed cell death ligand‐1 (PD‐L1) and programmed cell death ligand‐2 (PD‐L2) were retrospectively analyzed in patients with RMHNSCC treated with nivolumab.

Results

The positivity rates for TPS (PD‐L1), CPS (PD‐L1), TPS (PD‐L2), and CPS (PD‐L2) were 73.8%, 78.2%, 56.4%, and 78.2%, respectively. Patients with high TPS (PD‐L1), CPS (PD‐L1), or CPS (PD‐L1 and PD‐L2) showed significantly prolonged progression‐free survival. Favorable overall survival was associated with high CPS (PD‐L1 and PD‐L2) and low soluble PD‐L1 and PD‐L2 levels. The expressions of tissue and soluble PD‐L1/2 were not correlated.

Conclusions

Our study revealed that compared to PD‐L1 expression alone, dual expression of PD‐L1 and PD‐L2 in tissue or soluble form could be feasible biomarkers in patients with RMHNSCC who received nivolumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabB7-H1 AntigenHead and Neck NeoplasmsProgrammed Cell Death 1 Ligand 2 ProteinSquamous Cell Carcinoma of Head and NeckHumansMaleFemaleMiddle AgedRetrospective StudiesAgedBiomarkers, TumorAdultAntineoplastic Agents, ImmunologicalAged, 80 and over

Stichwörter der Autor:innen

head and neck carcinomanivolumabprogrammed cell death ligand‐1programmed cell death ligand‐2soluble forms

Substanzen

NivolumabB7-H1 AntigenProgrammed Cell Death 1 Ligand 2 ProteinCD274 protein, humanPDCD1LG2 protein, humanBiomarkers, TumorAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Otolaryngology-Head & Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
  • Department of Innovative Head & Neck Cancer Research and Treatment, Asahikawa Medical University, Asahikawa, Japan.

ORCID-Profile: Michihisa Kono, Takumi Kumai

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Sato, R., Komatsuda, H., Inoue, T., Wakisaka, R., Kono, M., Yamaki, H., Ohara, K., Kumai, T., Kishibe, K., Hayashi, T., & Takahara, M. (2024). Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD‐L1 and PD‐L2. Head & Neck. https://doi.org/10.1002/hed.27787

Vancouver

Sato R, Komatsuda H, Inoue T, Wakisaka R, Kono M, Yamaki H, et al. Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD‐L1 and PD‐L2. Head & Neck. 2024. doi:10.1002/hed.27787

BibTeX
@article{Sato2024,
  author = {Sato, Ryosuke and Komatsuda, Hiroki and Inoue, Takahiro and Wakisaka, Risa and Kono, Michihisa and Yamaki, Hidekiyo and Ohara, Kenzo and Kumai, Takumi and Kishibe, Kan and Hayashi, Tatsuya and Takahara, Miki},
  title = {Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD‐L1 and PD‐L2},
  journal = {Head & Neck},
  year = {2024},
  doi = {10.1002/hed.27787}
}
Kostenlos starten →